

Addendum: Systemic AL amyloidosis: current approach and future direction

Maroun Bou Zerdan¹, Lewis Nasr², Farhan Khalid³, Sabine Allam⁴, Youssef Bouferraa⁵, Saba Batool⁶, Muhammad Tayyeb⁷, Shubham Adroja⁸, Mahinbanu Mammadii¹, Faiz Anwer⁹, Shahzad Raza⁹ and Chakra P. Chaulagain¹⁰

¹Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA

²University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

³Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA

⁴Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon

⁵Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA

⁶Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA

⁷Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA

⁸Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA

⁹Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA

¹⁰Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA

Published: July 20, 2023

Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Research funding was obtained from the Cleveland Clinic Florida, Maroone Cancer Center, Malignant Hematology Research Fund.

Original article: Oncotarget. 2023; 14:384–394. <https://doi.org/10.18632/oncotarget.28415>